Infliximab (Remicade) in the treatment of psoriatic arthritis

Therapeutics and Clinical Risk Management

Volumn 2, Issue 4, 2006, Pages 389-400

  Mease, Philip ^a  

^a Seattle Rhumatology Associates   (United States)

Author keywords

Biologics; Psoriasis; Psoriatic arthritis; Spondyloarthropathies; TNF inhibition

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; PSORALEN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VITAMIN D;

CANCER RISK; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; INJECTION SITE REACTION; PATHOGENESIS; PSORIATIC ARTHRITIS; RANDOMIZATION; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN MANIFESTATION; ULTRAVIOLET RADIATION;

EID: 33845444791     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.4.389     Document Type: Review

References (97)

1. Abu-Shakra M, Gladman DD, Thorne JC, et al. 1995. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol, 22:241-5.
2. Antoni C, Deehant C, Hanns-Martin Lorenz PD, et al. 2002. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum, 47:506-12.
3. Antoni C, Krueger GG, de Vlam K, et al. 2005. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis, 64:1150-7.
4. Antoni CE, Kavanaugh A, Kirkham B, et al. 2005. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum, 52:1227-36.
5. Armstrong RD, Panayi GS, Welsh KI. 1983. Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann Rheum Dis, 42:142-6.
6. Askling J, Fored CM, Baecklund E, et al. 2005. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis, 64:1414-20.
7. Askling J, Fored CM, Brandt L, et al. 2005. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis, 64:1421-6.
8. Bertolini DR, Nedwin GE, Bringman TS, et al. 1986. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature, 319:516-18.
9. Blumberg BS, Bunim JJ, Calkins E, et al. 1964. ARA nomenclature and classification of arthritis and rheumatism. Arthritis Rheum, 7:93-7.
10. Bowcock AM. 2005. Understanding the pathogenesis of psoriasis, psoriatic arthritis, and autoimmunity via a fusion of molecular genetics and immunology, Immunol Res, 32:45-56.
11. Bowcock AM, Cookson WO. 2004. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet, 13:R43-55.
12. Braun J, Sieper J. 2003. Role of novel biological therapies in psoriatic arthritis: effects on joints and skin. BioDrugs, 17:187-99.
13. Brockbank J, Gladman D. 2002. Diagnosis and management of psoriatic arthritis. Drugs, 62:2447-57.
14. Burgess TL, Qian Y, Kaufman S, et al. 1999. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol, 145:527-38.
15. Cheifetz A, Smedley M, Martin S, et al. 2003. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol, 98:1315-24.
16. Costello P, Bresnihan B, O'Farrelly C, et al. 1999. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol, 26:1117-24.
17. Dayer JM, Beutler B, Cerami A. 1985. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med, 162:2163-8.
18. Delaunay C, Farrenq V, Marini-Portugal A, et al. 2005. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol, 32:2183-5.
19. Eastmond CJ, Wright V. 1979. The nail dystrophy of psoriatic arthritis. Ann Rheum Dis, 38:226-8.
20. Ellis CN, Krueger GG. 2001. Treatment of chronic plaque psoriasis by selective targeting of memory effeetor T lymphocytes. N Engl J Med, 345:248-55.
21. Espinoza LR, Aguilar JL, Espinoza CG, et al. 1994. Fibroblast function in psoriatic arthritis. I. Alteration of cell kinetics and growth factor responses. J Rheumatol, 21:1502-6.
22. Espinoza LR, Cuellar ML, Silveira LH. 1992. Psoriatic arthritis. Curr Opin Rheumatol, 4:470-8.
23. Espinoza LR, Espinoza CG, Cuellar ML, et al. 1994. Fibroblast function in psoriatic arthritis. II. Increased expression of beta platelet derived growth factor receptors and increased production of growth factor and cytokines. J Rheumatol, 21:1507-11.
24. Fournie B, Crognier L, Arnaud C, et al. 1999. Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Engl Ed, 66:446-56.
25. Gelfand JM, Gladman DD, Mease PJ, et al. 2005. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol, 53:573.
26. Giustizieri ML, Mascia F, Frezzolini A, et al. 2001. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct ehemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol, 107:871-7.
27. Gladman DD. 1993. Toward unraveling the mystery of psoriatic arthritis. Arthritis Rheum, 36:881-4.
28. Gladman DD. 1998. Psoriatic arthritis. Rheum Dis Clin North Am, 24:829-44, x.
29. Gladman DD. 2003. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum, 33:29-37.
30. Gladman DD. 2005. Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. Drugs, 65:1223-38.
31. Gladman DD, Anhorn KA, Schachter RK, et al. 1986. HLA antigens in psoriatic arthritis. J Rheumatol, 13:586-92.
32. Gladman DD, Antoni C, Mease P, et al. 2005. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis, 64(Suppl 2):ii14-7.
33. Gladman DD, Cheung C, Ng CM, et al. 1999. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol, 60:259-61.
34. Gladman DD, Farewell VT, Kopciuk KA, et al. 1998. HLA markers and progression in psoriatic arthritis. J Rheumatol, 25:730-3.
35. Gladman DD, Farewell VT, Pellett F, et al. 2003. HLA is a candidate region for psoriatic arthritis, evidence for excessive HLA sharing in sibling pairs. Hum Immunol, 64:887-9.
36. Gladman DD, Shuckett R, Russell ML, et al. 1987. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med, 62:127-41.
37. Gomez-Reino J J, Carmona L. 2006. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther, 8:R29.
38. Gordon KB, Papp KA, Hamilton TK, et al. 2003. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA, 290:3073-80.
39. Gottlieb AB, Evans R, Li S, et al. 2004. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol, 51:534-42.
40. Helliwell PS, Taylor WJ. 2005. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis, 64(Suppl 2):ii3-8.
41. Husted JA, Gladman DD, Farewell VT, et al. 2001. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum, 45:151-8.
42. Karason A, Gudjonsson JE, Upmanyu R, et al. 2003. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet, 72:125-31.
43. Kavanaugh A, Antoni C, Krueger GG, et al. 2006. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis, 65:471-7.
44. Kavanaugh A, Antoni CE, Gladman DD, et al. 2006. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year. Ann Rheum Dis, 65:1038-43.
45. Keystone EC, Kavanaugh AF, Sharp JT, et al. 2004. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum, 50:1400-11.
46. Korman NJ, Moul DK. 2005. Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use. Semin Cutan Med Surg, 24:10-8.
47. Lacey DL, Timms E, Tan HL, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93:165-76.
48. Langevitz P, Buskila D, Gladman DD. 1990. Psoriatic arthritis precipitated by physical trauma. J Rheumatol, 17:695-7.
49. Lebwohl M, Ting PT, Koo JY. 2005. Psoriasis treatment: traditional therapy. Ann Rheum Dis, 64 (Suppl 2):ii83-6.
50. Lebwohl M, Tyring SK, Hamilton TK, et al. 2003. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med, 349:2004-13.
51. Leonard DG, O'Duffy JD, Rogers RS. 1978. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc, 53:511-18.
52. Mader R, Gladman DD, Long J, et al. 1995. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med, 18:139-43.
53. Marguerie L, Flipo RM, Grardel B, et al. 2002. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine, 69:275-81.
54. Mease P. 2003. Psoriatic arthritis/psoriasis. In: Smolen JS (ed). Targeted Therapies in Rheumatology. London: Martin Dunitz Ltd. p 525-48.
55. Mease P. 2004a. Efalizumab in psoriatic arthritis. Toronto, Canada: International Psoriasis Society.
56. Mease P. 2004b. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis, 63:755-8.
57. Mease P, Gladman D, Keystone E. 2005. Efficacy of alefacept in combination with methotrexate in the treatment of psoriatic arthritis. Ann Rheum Dis, 64:324.
58. Mease P, Goffe BS. 2005. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol, 52:1-19.
59. Mease PJ, Antoni CE. 2005. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis, 64(Suppl 2):ii78-82.
60. Mease PJ, Gladman DD, Keystone EC. 2006. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum, 54: 1638-45.
61. Mease PJ, Gladman DD, Ritchlin CT, et al. 2005. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum, 52:3279-89.
62. Mease PJ, Goffe BS, Metz J, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet, 356:385-90.
63. Mease PJ, Kivitz AJ, Burch FX, et al. 2004. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum, 50:2264-72.
64. Moll JM, Wright V. 1973a. Familial occurrence of psoriatic arthritis. Ann Rheum Dis, 32:181-201.
65. Moll JM, Wright V. 1973b. Psoriatic arthritis. Semin Arthritis Rheum, 3:55-78.
66. Nakashima T, Wada T, Penninger JM. 2003. RANKL and RANK as novel therapeutic targets for arthritis. Curt Opin Rheumatol, 15:280-7.
67. Nash P, Clegg DO. 2005. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis, 64(Suppl 2):ii74-7.
68. Ory PA. 2003. Radiography in the assessment of musculoskeletal conditions. Best Pract Res Clin Rheumatol, 17:495-512.
69. Ory PA, Gladman DD, Mease PJ. 2005. Psoriatic arthritis and imaging. Ann Rheum Dis, 64(Suppl 2):ii55-7.
70. Pipitone N, Kingsley GH, Manzo A, et al. 2003. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford), 42:1138-48.
71. Rahman P, Bartlett S, Siannis F, et al. 2003. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet, 73:677-81.
72. Rahman P, Gladman DD, Cook RJ, et al. 1998. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol, 25:1957-61.
73. Reich K, Nestle FO, Papp K, et al. 2005. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet, 366:1367-74.
74. Reich K, Nestle FO, Papp K, et al. 2006. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol, 154: 1161-8.
75. Remicade. 2006a. Remicade package insert, EU. Malvern, PA: Centocor, Inc.
76. Remicade. 2006b. Remicade package insert, US. Malvern, PA: Centocor, Inc.
77. Ritchlin C, Anandarajaha A, Totterman S, et al. 2004. Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis [abstract]. Ann Rheum Dis, 63:403.
78. Ritchlin C, Haas-Smith SA, Hicks D, et al. 1998. Patterns of cytokine production in psoriatic synovium. J Rheumatol, 25:1544-52.
79. Ritchlin CT, Haas-Smith SA, Li P, et al. 2003. Mechanisms of TNF-alpha-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest, 111:821-31.
80. Saklatvala J. 1986. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature, 322:547-9.
81. Salonen S. 2003. The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,900 members of European psoriasis patients associations (poster).
82. Shbeeb M, Uramoto KM, Gibson LE, et al. 2000. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol, 27:1247-50.
83. Soderlin MK, Borjesson O, Kautiainen H, et al. 2002. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis, 61:911-15.
84. Sokoll KB, Helliwell PS. 2001. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol, 28:1842-6.
85. Swanbeck G, Inerot A, Martinsson T, et al. 1997. Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol, 137:939-42.
86. Taylor W. 2006. ClASsification criteria for Psoriatic ARthritis: results from the CASPAR study. Arthritis Rheum, 54:2665-73.
87. Terajima S, Higaki M, Igarashi Y, et al. 1998. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch Dermatol Res, 290:246-52.
88. Van den Bosch F, Kruithof E, Baeten D, et al. 2000. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis, 59:428-33.
89. Van der Heijde D, Gladman D, Kavanaugh A, et al. 2005. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week results from IMPACT 2. Arthritis Rheum, 52:S281.
90. Veale D, Rogers S, Fitzgerald O. 1995. Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br J Dermatol, 132:32-8.
91. Veale D, Yanni G, Rogers S, et al. 1993. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum, 36:893-900.
92. Veale DJ, Ritchlin C, FitzGerald O. 2005. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis, 64(Suppl 2):ii26-9.
93. Wassenherg S, Fischer-Kahle V, Herborn G, et al. 2001. A method to score radiographic change in psoriatic arthritis. Z Rheumatol, 60:156-66.
94. Wick MC, Ernestam S, Lindblad S, et al. 2005. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol, 34:353-8.
95. Wong K, Gladman DD, Husted J, et al. 1997. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum, 40:1868-72.
96. Wright V. 1959. Rheumatism and psoriasis: a re-evaluation. Am J Med, 27:454-62.
97. Zachariae H. 2003. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol, 4:441-7.